LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer.

    Corbacioglu, Selim / Grupp, Stephan A / Richardson, Paul Gerard / Duarte, Rafael / Pagliuca, Antonio / Ruutu, Tapani / Mahadeo, Kris / Carreras, Enric

    Bone marrow transplantation

    2023  Volume 58, Issue 8, Page(s) 839–841

    MeSH term(s) Humans ; Hepatic Veno-Occlusive Disease/etiology ; Hepatic Veno-Occlusive Disease/prevention & control ; Vascular Diseases ; Hematopoietic Stem Cell Transplantation
    Language English
    Publishing date 2023-05-25
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    DOI 10.1038/s41409-023-02007-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

    Roccaro, Aldo Maria / Hideshima, Teru / Raje, Noopur / Kumar, Shaji / Ishitsuka, Kenji / Yasui, Hiroshi / Shiraishi, Norihiko / Ribatti, Domenico / Nico, Beatrice / Vacca, Angelo / Dammacco, Franco / Richardson, Paul Gerard / Anderson, Kenneth Carl

    Cancer research

    2006  Volume 66, Issue 1, Page(s) 184–191

    Abstract: Bone marrow angiogenesis plays an important role in the pathogenesis and progression in multiple myeloma. Recent studies have shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug resistance in vitro and in ... ...

    Abstract Bone marrow angiogenesis plays an important role in the pathogenesis and progression in multiple myeloma. Recent studies have shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug resistance in vitro and in vivo; however, its antiangiogenic activity in the bone marrow milieu has not yet been defined. In the present study, we examined the effects of bortezomib on the angiogenic phenotype of multiple myeloma patient-derived endothelial cells (MMEC). At clinically achievable concentrations, bortezomib inhibited the proliferation of MMECs and human umbilical vein endothelial cells in a dose-dependent and time-dependent manner. In functional assays of angiogenesis, including chemotaxis, adhesion to fibronectin, capillary formation on Matrigel, and chick embryo chorioallantoic membrane assay, bortezomib induced a dose-dependent inhibition of angiogenesis. Importantly, binding of MM.1S cells to MMECs triggered multiple myeloma cell proliferation, which was also abrogated by bortezomib in a dose-dependent fashion. Bortezomib triggered a dose-dependent inhibition of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) secretion by the MMECs, and reverse transcriptase-PCR confirmed drug-related down-regulation of VEGF, IL-6, insulin-like growth factor-I, Angiopoietin 1 (Ang1), and Ang2 transcription. These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu.
    MeSH term(s) Angiogenesis Inhibitors/pharmacology ; Angiopoietin-1/biosynthesis ; Angiopoietin-1/genetics ; Angiopoietin-2/biosynthesis ; Angiopoietin-2/genetics ; Animals ; Antineoplastic Agents/pharmacology ; Boronic Acids/pharmacology ; Bortezomib ; Cell Growth Processes/drug effects ; Cells, Cultured ; Chick Embryo ; Chorioallantoic Membrane/blood supply ; Dose-Response Relationship, Drug ; Down-Regulation/drug effects ; Endothelial Cells/drug effects ; Endothelial Cells/secretion ; Humans ; Insulin-Like Growth Factor I/biosynthesis ; Insulin-Like Growth Factor I/genetics ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/biosynthesis ; Interleukin-6/genetics ; Interleukin-6/secretion ; Multiple Myeloma/blood supply ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/genetics ; Neovascularization, Pathologic/pathology ; Neovascularization, Physiologic/drug effects ; Pyrazines/pharmacology ; Reverse Transcriptase Polymerase Chain Reaction ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/biosynthesis ; Vascular Endothelial Growth Factor A/genetics ; Vascular Endothelial Growth Factor A/secretion
    Chemical Substances Angiogenesis Inhibitors ; Angiopoietin-1 ; Angiopoietin-2 ; Antineoplastic Agents ; Boronic Acids ; Interleukin-6 ; Pyrazines ; Vascular Endothelial Growth Factor A ; Insulin-Like Growth Factor I (67763-96-6) ; Bortezomib (69G8BD63PP)
    Language English
    Publishing date 2006-01-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-05-1195
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.135/5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.

    Richardson, Paul Gerard Guy / Barlogie, Bart / Berenson, James / Singhal, Seema / Jagannath, Sundar / Irwin, David / Rajkumar, S Vincent / Hideshima, Teru / Xiao, Hugh / Esseltine, Dixie / Schenkein, David / Anderson, Kenneth C

    Blood

    2005  Volume 106, Issue 9, Page(s) 2977–2981

    Abstract: Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in down-regulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. ... ...

    Abstract Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in down-regulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 twice weekly for 2 weeks every 3 weeks for up to 8 cycles in a phase 2 trial. Using European Group for Blood and Marrow Transplantation criteria, the response rate (complete or partial response) to bortezomib alone was 27% and was not associated with sex, race, performance status, isotype, chromosome 13 deletion, number or type of previous therapies, or concentration of hemoglobin or beta2-microglobulin. By multivariate analysis, factors associated with lower response were being age 65 or older versus younger than 65 (19% vs 32%; P < .05) and plasma-cell infiltration in bone marrow greater than 50% versus 50% or less (20% vs 35%; P < .05). Factors that may be indicative of tumor burden (bone marrow plasma-cell infiltration greater than 50%, hypoalbuminemia, thrombocytopenia) were predictive of overall survival. Chromosome 13 deletion and elevated beta2-microglobulin, generally considered poor prognostic factors, were not predictive of poor outcome with bortezomib in this study.
    MeSH term(s) Aged ; Boronic Acids/therapeutic use ; Bortezomib ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Pyrazines/therapeutic use ; Recurrence ; Treatment Outcome
    Chemical Substances Boronic Acids ; Pyrazines ; Bortezomib (69G8BD63PP)
    Language English
    Publishing date 2005-07-14
    Publishing country United States
    Document type Clinical Trial ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2005-02-0691
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top